Prophase Labs Inc Says Pharmaloz Plan Is To Build Capacity With A Goal To Attain A Revenue Run-rate Of $60 To $80M By Year-End 2024; Pharmaloz Is Projected To Achieve A Run-Rate Of $15M In Annualized Revenues & Run-Rate Of $3M+ In Gross Profit During Q1
Portfolio Pulse from Benzinga Newsdesk
Prophase Labs Inc has announced plans for its Pharmaloz division to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by the end of 2024. Pharmaloz is projected to achieve a run-rate of $15 million in annualized revenues and a run-rate of over $3 million in gross profit during Q1.
October 17, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prophase Labs' Pharmaloz division is expected to significantly increase its revenue and gross profit run-rates over the next few years, which could positively impact the company's overall financial performance.
The news directly pertains to Prophase Labs and its Pharmaloz division's future revenue and profit goals. If these targets are met, it could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100